For more than fifteen years, Apple has quietly pursued one of medicine's most elusive engineering goals: reading blood sugar without breaking skin. A recent leadership change — moving the project to an engineer known for turning research into reality — suggests the long vigil may be entering a new phase. If the work succeeds, it would not merely add a feature to a watch; it would quietly transform the daily lives of millions of people who currently measure their survival in needle pricks.
Apple Shifts Blood Sugar Monitoring Project to Senior Engineer, Signaling Progress
Successful development could significantly improve quality of life for millions of people with diabetes by eliminating painful daily blood glucose monitoring.
After more than a decade and a half of development, the work may finally be reaching a stage where it can accelerate
Mark
Why move the project now, after fifteen years? What changed?
Mimi
The timing suggests Apple thinks they've solved enough of the hard physics problems that a different kind of engineer—one who specializes in turning research into products—can actually move it forward. It's not about the science anymore. It's about engineering and shipping.
Mark
And Zongjian Chen is that person?
Mimi
That's the bet. He's known inside Apple for taking complex ideas and making them real. If anyone can navigate the regulatory path and the manufacturing challenges, it's him.
Mark
How close are they, really?
Mimi
Honestly, no one outside Apple knows. But fifteen years in the lab suggests the core technology works. The question now is whether it works well enough, fast enough, and cheaply enough to put in a consumer product.
Mark
What's the actual barrier at this point?
Mimi
Probably manufacturing at scale, battery life, and regulatory approval. The laser system has to be tiny, reliable, and accurate. Those are engineering problems, not science problems. That's Chen's domain.
Mark
If it works, what changes for people with diabetes?
Mimi
Everything, really. No more finger pricks. No more separate devices. Just a watch that tells you your blood sugar whenever you need to know. That's a different life.
El Pulso
- Apple's non-invasive glucose monitoring project has spent over fifteen years in the lab, held back by the sheer difficulty of reading chemistry through living skin with a device small enough to wear.
- The reassignment of the project to Zongjian Chen — an engineer with a reputation for actually shipping products — has sent a signal inside Apple that the work may finally be crossing from research into development.
- The technology uses lasers to read glucose concentrations in the fluid beneath the skin, a method elegant in theory but brutally demanding in practice: light scatters, skin varies, and the margins for error are razor-thin.
- Even with new leadership and renewed momentum, commercial availability remains years away and is not guaranteed — regulatory approval alone represents a formidable final obstacle.
- The stakes are quietly enormous: success would free millions of people from the ritual of daily finger pricks and separate monitoring devices, folding a medical necessity into something they already wear on their wrist.
For more than fifteen years, Apple has quietly pursued one of medicine's most elusive engineering goals: reading blood sugar without breaking skin. A recent leadership change — moving the project to an engineer known for turning research into reality — suggests the long vigil may be entering a new phase. If the work succeeds, it would not merely add a feature to a watch; it would quietly transform the daily lives of millions of people who currently measure their survival in needle pricks.
Apple has spent more than fifteen years trying to solve a problem that sits at the intersection of optics, biology, and miniaturization: measuring blood sugar without drawing blood. The goal has always been to bring this capability to the Apple Watch, letting people with diabetes check their glucose the way they check the time — no needle, no separate device, just a glance at the wrist.
For most of that time, the project lived in the quieter corners of Apple's research labs. Then came a notable shift. Bloomberg's Mark Gurman reported that Apple moved the project's leadership from Tim Millet, who oversees platform architecture, to Zongjian Chen, a senior engineer known across the company for one particular quality: he delivers. Inside Apple, that reassignment reads as more than routine reorganization — it suggests the work may be maturing toward something that can actually be built and sold.
The technical approach relies on lasers emitting specific wavelengths of light into the tissue just beneath the skin, where interstitial fluid collects. Glucose in that fluid absorbs the light in a characteristic way, and the returning signal — analyzed by an algorithm — reveals the concentration. The system could also detect early markers of prediabetes, broadening its reach beyond those already managing the disease.
The engineering obstacles are formidable. Skin scatters light unpredictably. Glucose concentrations are small. The sensor must fit inside a watch and run on a watch battery, while producing readings accurate enough to be medically meaningful. Those constraints explain why fifteen years of effort have not yet produced a product.
Apple is making no promises. Years of further development, testing, and regulatory approval stand between the current research and any consumer release — and moonshot projects sometimes simply fail. But the potential reward is proportionate to the difficulty: millions of people currently manage diabetes through repeated daily finger pricks or by wearing dedicated monitors alongside their other devices. A non-invasive solution built into a watch they might already own would quietly reshape what it means to live with the disease.
Apple has been chasing a particular dream for more than fifteen years: a way to measure blood sugar without drawing blood. The company wants to build this capability into the Apple Watch, which would let millions of people with diabetes check their glucose levels the way they check their heart rate—by glancing at their wrist, no needle required.
For years, the project existed in the background of Apple's research labs, moving forward in fits and starts. Then, recently, something shifted. According to Bloomberg reporter Mark Gurman, Apple moved the project from Tim Millet, who oversees platform architecture, to Zongjian Chen, a senior engineer responsible for advanced technologies across the company. The change might sound like a routine reorganization. But inside Apple, it reads differently. Chen has a reputation for shipping things—for taking research and turning it into products people can actually use.
Gurman framed the leadership transition as a positive signal. After more than a decade and a half of development, the work may finally be reaching a stage where it can accelerate toward something consumers might hold in their hands. "Some view the transition as a sign the work may finally be progressing to a point where Chen, known as someone who delivers, can ramp up development of the technology into an eventual consumer-grade offering," Gurman wrote.
The technical approach Apple has settled on relies on lasers. The system emits specific wavelengths of light into the tissue just beneath the skin, where interstitial fluid pools—the liquid that seeps out of capillaries. Glucose in that fluid absorbs the light. The light bounces back to a sensor, and the pattern of reflection reveals the glucose concentration. An algorithm then translates that optical signal into a blood sugar reading. The system could also flag early warning signs of prediabetes, expanding its usefulness beyond people already managing diabetes.
It is a genuinely difficult engineering problem. Skin is opaque and variable. Light scatters. Glucose concentrations are small. The sensor has to be small enough to fit in a watch. The battery has to last. The readings have to be accurate enough to matter. These constraints have kept the project in the lab for fifteen years.
Even with Chen now leading the effort, Apple is not promising anything soon. The company still faces years of development, testing, and regulatory approval before this feature could reach the market—if it reaches the market at all. Moonshot projects fail. Technical breakthroughs don't always materialize. But if Apple cracks this one, the payoff would be substantial. Millions of people with diabetes currently prick their fingers multiple times a day to monitor their blood sugar, or wear separate continuous glucose monitors on top of their other devices. A non-invasive option built into a watch they might already own would reshape the daily experience of managing the disease. It would be the kind of innovation that justifies the years of patient, unglamorous work in the lab.
Citas Notables
Some view the transition as a sign the work may finally be progressing to a point where Chen, known as someone who delivers, can ramp up development of the technology into an eventual consumer-grade offering— Mark Gurman, Bloomberg
Quieres la nota completa?
Lee el original en MacRumors ↗
Technology